LVTX is a pharmaceutical company focused on biologicals for advanced prostate carcinoma.
It recently secured a collaboration agreement with Merck to assist in the clinical trials and
the financial burdens it imposes in a quid pro quo related to a share of product margins in the
future. On the 15-minute chart, LVTX burst out of a long-standing consolidation...